Table 3.
Ranking of findings by strength of evidence across platforms
| NanoString | TLDA | qPCR | ||||
|---|---|---|---|---|---|---|
| miRNA | p | FC | p | FC | p | FC |
| miR-31 | 0.0059 | -3.9 | 0.0026 | -10.3 | 0.0040 | -9.2 |
| miR-125b | 0.0419 | -2.5 | 0.0066 | -4.5 | 0.0090 | -3.6 |
| miR-150 | 0.0071 | -1.9 | 0.0261 | -1.6 | 0.0003 | -1.6 |
| miR-31* | NA | 0.0043 | -10.1 | 0.0195 | -8.5 | |
| miR-9 | 0.0033 | 1.8 | 0.0489 | 4.1 | NA | |
| miR-181b | 0.0092 | 1.8 | NA | 0.0400 | 1.6 | |
| miR-29a | < 0.1 | 0.0117 | -1.5 | 0.0180 | -1.7 | |
| let-7g | 0.0004 | -1.7 | 0.0028 | -1.5 | NS | |
| miR-16 | NS | 0.0061 | 1.5 | 0.0001 | 1.5 | |
| miR-146b-5p | 0.0025 | -2.6 | 0.0020 | -2.7 | NS | |
| miR-155 | 0.0071 | 1.5 | NS | 0.0690 | 1.3 | |
| miR-34a | < 0.1 | 0.0514 | 3.6 | 0.0040 | 3.1 | |
For NanoString, TaqMan low-density array (TLDA), and quantitative PCR (qPCR), miRNAs are presented according to the estimated strength of evidence for differential regulation between viremic patients and controls: bold (p < 0.05 for each method with which the respective miRNA was measured); italics (p < 0.05 for two of three); and regular font (p < 0.05 for one platform and p < 0.1 for at least one other). Each of the listed miRNAs had relatively high levels of expression across samples: more than two standard deviations above background (NanoString) and/or amplifying before a threshold cycle of 30 by TaqMan assay. Abbreviations: p = p value; FC = mean fold difference from control (positive or negative as indicated); NS (not significant) refers here to p > 0.1; NA: not measured with the indicated method. miR-150 values for NanoString and TLDA are rendered in bold italics to indicate quantile normalization limitations at expression extremes (miR-150 is one of the most abundant miRNAs in PBMC).